|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TIPARP |
Gene summary for TIPARP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TIPARP | Gene ID | 25976 |
| Gene name | TCDD inducible poly(ADP-ribose) polymerase | |
| Gene Alias | ARTD14 | |
| Cytomap | 3q25.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q7Z3E1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25976 | TIPARP | AEH-subject1 | Human | Endometrium | AEH | 2.50e-12 | 4.05e-01 | -0.3059 |
| 25976 | TIPARP | AEH-subject4 | Human | Endometrium | AEH | 8.77e-07 | 4.21e-01 | -0.2657 |
| 25976 | TIPARP | AEH-subject5 | Human | Endometrium | AEH | 2.86e-09 | 5.17e-01 | -0.2953 |
| 25976 | TIPARP | EEC-subject1 | Human | Endometrium | EEC | 3.17e-02 | 2.98e-01 | -0.2682 |
| 25976 | TIPARP | EEC-subject3 | Human | Endometrium | EEC | 2.68e-02 | 2.60e-01 | -0.2525 |
| 25976 | TIPARP | EEC-subject4 | Human | Endometrium | EEC | 1.70e-10 | 4.90e-01 | -0.2571 |
| 25976 | TIPARP | EEC-subject5 | Human | Endometrium | EEC | 2.93e-14 | 5.15e-01 | -0.249 |
| 25976 | TIPARP | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.87e-02 | -1.60e-01 | -0.1883 |
| 25976 | TIPARP | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.70e-05 | -4.43e-02 | -0.1917 |
| 25976 | TIPARP | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.15e-02 | -1.07e-01 | -0.1916 |
| 25976 | TIPARP | LZE4T | Human | Esophagus | ESCC | 7.49e-07 | 4.14e-01 | 0.0811 |
| 25976 | TIPARP | LZE7T | Human | Esophagus | ESCC | 3.47e-02 | 5.57e-01 | 0.0667 |
| 25976 | TIPARP | LZE8T | Human | Esophagus | ESCC | 2.96e-06 | 5.76e-01 | 0.067 |
| 25976 | TIPARP | LZE20T | Human | Esophagus | ESCC | 9.55e-05 | 4.67e-02 | 0.0662 |
| 25976 | TIPARP | LZE22D1 | Human | Esophagus | HGIN | 2.72e-03 | -2.89e-01 | 0.0595 |
| 25976 | TIPARP | LZE24T | Human | Esophagus | ESCC | 6.24e-03 | 2.79e-01 | 0.0596 |
| 25976 | TIPARP | LZE21T | Human | Esophagus | ESCC | 6.10e-05 | 9.75e-01 | 0.0655 |
| 25976 | TIPARP | P1T-E | Human | Esophagus | ESCC | 6.51e-06 | 1.44e+00 | 0.0875 |
| 25976 | TIPARP | P2T-E | Human | Esophagus | ESCC | 2.66e-30 | 1.22e+00 | 0.1177 |
| 25976 | TIPARP | P4T-E | Human | Esophagus | ESCC | 2.04e-10 | 2.44e-01 | 0.1323 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004217616 | Endometrium | AEH | regulation of protein catabolic process | 100/2100 | 391/18723 | 9.58e-16 | 3.59e-13 | 100 |
| GO:000989616 | Endometrium | AEH | positive regulation of catabolic process | 104/2100 | 492/18723 | 9.38e-11 | 1.10e-08 | 104 |
| GO:00614589 | Endometrium | AEH | reproductive system development | 88/2100 | 427/18723 | 9.50e-09 | 6.41e-07 | 88 |
| GO:00486089 | Endometrium | AEH | reproductive structure development | 87/2100 | 424/18723 | 1.43e-08 | 9.12e-07 | 87 |
| GO:004573216 | Endometrium | AEH | positive regulation of protein catabolic process | 56/2100 | 231/18723 | 1.60e-08 | 9.99e-07 | 56 |
| GO:00605376 | Endometrium | AEH | muscle tissue development | 83/2100 | 403/18723 | 2.57e-08 | 1.50e-06 | 83 |
| GO:00016556 | Endometrium | AEH | urogenital system development | 67/2100 | 338/18723 | 2.30e-06 | 6.76e-05 | 67 |
| GO:00720015 | Endometrium | AEH | renal system development | 61/2100 | 302/18723 | 3.43e-06 | 9.24e-05 | 61 |
| GO:00018224 | Endometrium | AEH | kidney development | 57/2100 | 293/18723 | 2.25e-05 | 4.35e-04 | 57 |
| GO:00465452 | Endometrium | AEH | development of primary female sexual characteristics | 24/2100 | 100/18723 | 2.27e-04 | 2.75e-03 | 24 |
| GO:00085852 | Endometrium | AEH | female gonad development | 23/2100 | 95/18723 | 2.65e-04 | 3.09e-03 | 23 |
| GO:00466602 | Endometrium | AEH | female sex differentiation | 25/2100 | 114/18723 | 7.30e-04 | 6.99e-03 | 25 |
| GO:00075482 | Endometrium | AEH | sex differentiation | 46/2100 | 276/18723 | 3.91e-03 | 2.64e-02 | 46 |
| GO:00451372 | Endometrium | AEH | development of primary sexual characteristics | 39/2100 | 227/18723 | 4.45e-03 | 2.92e-02 | 39 |
| GO:00084062 | Endometrium | AEH | gonad development | 38/2100 | 221/18723 | 4.87e-03 | 3.08e-02 | 38 |
| GO:004217617 | Endometrium | EEC | regulation of protein catabolic process | 103/2168 | 391/18723 | 3.54e-16 | 1.52e-13 | 103 |
| GO:000989617 | Endometrium | EEC | positive regulation of catabolic process | 108/2168 | 492/18723 | 2.55e-11 | 3.64e-09 | 108 |
| GO:004573217 | Endometrium | EEC | positive regulation of protein catabolic process | 59/2168 | 231/18723 | 2.69e-09 | 2.01e-07 | 59 |
| GO:006145815 | Endometrium | EEC | reproductive system development | 91/2168 | 427/18723 | 4.54e-09 | 3.13e-07 | 91 |
| GO:004860814 | Endometrium | EEC | reproductive structure development | 90/2168 | 424/18723 | 6.77e-09 | 4.41e-07 | 90 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TIPARP | SNV | Missense_Mutation | c.443N>T | p.Ser148Ile | p.S148I | Q7Z3E1 | protein_coding | tolerated_low_confidence(0.09) | benign(0.058) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| TIPARP | SNV | Missense_Mutation | c.1731N>C | p.Lys577Asn | p.K577N | Q7Z3E1 | protein_coding | tolerated(0.07) | possibly_damaging(0.874) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TIPARP | SNV | Missense_Mutation | c.244G>A | p.Glu82Lys | p.E82K | Q7Z3E1 | protein_coding | tolerated_low_confidence(0.71) | benign(0.015) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD | |
| TIPARP | insertion | Frame_Shift_Ins | novel | c.559_560insGACTTTATTGGGCACCTAGGAT | p.Ile188LeufsTer24 | p.I188Lfs*24 | Q7Z3E1 | protein_coding | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| TIPARP | insertion | Frame_Shift_Ins | novel | c.1587_1588insA | p.Leu530IlefsTer19 | p.L530Ifs*19 | Q7Z3E1 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| TIPARP | insertion | In_Frame_Ins | novel | c.1588_1589insCAGCACATTTGGAAGAAAACA | p.Leu530delinsSerAlaHisLeuGluGluAsnIle | p.L530delinsSAHLEENI | Q7Z3E1 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| TIPARP | deletion | Frame_Shift_Del | novel | c.260delN | p.Glu87AspfsTer3 | p.E87Dfs*3 | Q7Z3E1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TIPARP | SNV | Missense_Mutation | rs745377501 | c.1097G>A | p.Arg366Gln | p.R366Q | Q7Z3E1 | protein_coding | tolerated(0.18) | benign(0.044) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TIPARP | SNV | Missense_Mutation | rs767797746 | c.1165N>G | p.Ile389Val | p.I389V | Q7Z3E1 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| TIPARP | SNV | Missense_Mutation | novel | c.1778N>T | p.Thr593Met | p.T593M | Q7Z3E1 | protein_coding | tolerated(0.06) | probably_damaging(0.986) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |